BGOG-ov89/DESTINY-Ovarian01

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer

Open
Trial drug
Trastuzumab Deruxtecan
Grade
High grade
Prior lines
Frontline
Histology
Serous, Mucinous Endometrioid Clear-cell Carcinocarcoma
Phase
III

Treatment

This study consists of two different treatment options:

  • Trastuzumab Deruxtecan + bevacizumab

  • Bevacizumab

The treatment is given every 3 weeks as first-line maintenance therapy. 

Treatment duration

Up to 16 cycles of maintenance therapy is allowed.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.